The DOI matches its Crossref record; 201 of the 203 references it cites were found in a registry or an index.
STAT3, a Master Regulator of Anti-Tumor Immune Response
Open accessAbstract
Immune cells in the tumor microenvironment regulate cancer growth. Thus cancer progression is dependent on the activation or repression of transcription programs involved in the proliferation/activation of lymphoid and myeloid cells. One of the main transcription factors involved in many of these pathways is the signal transducer and activator of transcription 3 (STAT3). In this review we will focus on the role of STAT3 and its regulation, e.g., by phosphorylation or acetylation in immune cells and how it might impact immune cell function and tumor progression. Moreover, we will review the ability of STAT3 to regulate checkpoint inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“IL-6 is also a key factor in inflammation, autoimmunity and cancer, with its effect mainly exerted through the IL-6–signal transducer and activator of transcription 3 (STAT3) pathway (18–26, 61–65).”
From IL-6 in inflammation, autoimmunity and cancer (2021) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, NF-κB and STAT3 play crucial roles in cancer development and progression (19, 25, 67, 279).”
From IL-6 in inflammation, autoimmunity and cancer (2021) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Other inhibitors against the IL-6–STAT3 signaling pathway are under development (19, 21, 24–26, 76, 374).”
From IL-6 in inflammation, autoimmunity and cancer (2021) · cites this paper as [25]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Much evidence has accumulated to show that STAT3 functions as an inhibitor for DC differentiation, maturation and antigen-presenting ability, and therefore STAT3 inhibits tumor immunity by interfering with DC functions (Fig. 2) (25).”
From IL-6 in inflammation, autoimmunity and cancer (2021) · cites this paper as [25]
The cited source says what the claim attributes to it.
In the citing paper
“MDSC function is dependent on STAT3 (25).”
From IL-6 in inflammation, autoimmunity and cancer (2021) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Ivanov, I. I., McKenzie, B. S., Zhou, L., Tadokoro, C. E., Lepelley, A., Lafaille, J. J., Cua, D. J., & Littman, D. R. (2006) · Cell · doi:10.1016/j.cell.2006.07.035 · Cited by 5,145
Chen, W., Jin, W., Hardegen, N. J., Lei, K.-J., Li, L., Marinos, N. J., McGrady, G., & Wahl, S. M. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030152 · Cited by 4,678
The Dendritic Cell System and its Role in Immunogenicity
Steinman, R. M. (1991) · Annual Review of Immunology · doi:10.1146/annurev.iy.09.040191.001415 · Cited by 4,659
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M. J., Obenauf, A. C., Angell, H. K., Fredriksen, T., Lafontaine, L., Berger, A., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.10.003 · Cited by 4,455
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383
Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments
Grauer, O. M., Wesseling, P., & Adema, G. J. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00315.x · Cited by 4,023
A Novel Transcription Factor, T-bet, Directs Th1 Lineage Commitment
Szabo, S. J., Kim, S. T., Costa, G. L., Zhang, X., Fathman, C. G., & Glimcher, L. H. (2000) · Cell · doi:10.1016/s0092-8674(00)80702-3 · Cited by 3,589
Tumour-educated macrophages promote tumour progression and metastasis
Pollard, J. W. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1256 · Cited by 3,414
M-1/M-2 Macrophages and the Th1/Th2 Paradigm
Mills, C. D., Kincaid, K., Alt, J. M., Heilman, M. J., & Hill, A. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.12.6166 · Cited by 3,287
Macrophage activation and polarization
Martinez, F. O. (2008) · Frontiers in Bioscience · doi:10.2741/2692 · Cited by 3,160
Zheng, W.-P., & Flavell, R. A. (1997) · Cell · doi:10.1016/s0092-8674(00)80240-8 · Cited by 2,384
Distinct role of macrophages in different tumor microenvironments
Lewis, C. E., & Pollard, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4005 · Cited by 2,225
Zhou, L., Ivanov, I. I., Spolski, R. J., Min, R., Shenderov, K., Egawa, T., Levy, D. E., Leonard, W. J., & Littman, D. R. (2007) · Nature Immunology · doi:10.1038/ni1488 · Cited by 2,210
CD4+CD25+ suppressor T cells: more questions than answers
Shevach, E. M. (2002) · Nature reviews. Immunology · doi:10.1038/nri821 · Cited by 2,097
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
Garcia-Diaz, A., Shin, D. S., Moreno, B. H., Saco, J., Escuin-Ordinas, H., Rodriguez, G. A., Zaretsky, J. M., Sun, L., Hugo, W., Wang, X., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.04.031 · Cited by 1,942
Sakaguchi, S. (2000) · Cell · doi:10.1016/s0092-8674(00)80856-9 · Cited by 1,812
T Helper 17 Lineage Differentiation Is Programmed by Orphan Nuclear Receptors RORα and RORγ
Yang, X. O., Pappu, B. P., Nurieva, R., Akimzhanov, A., Kang, H. S., Chung, Y., Ma, L., Shah, B., Panopoulos, A. D., Schluns, K. S., et al. (2008) · Immunity · doi:10.1016/j.immuni.2007.11.016 · Cited by 1,605
SOCS proteins, cytokine signalling and immune regulation
Yoshimura, A., Naka, T., & Kubo, M. (2007) · Nature Reviews Immunology · doi:10.1038/nri2093 · Cited by 1,580
STAT3 Regulates Cytokine-mediated Generation of Inflammatory Helper T Cells
Yang, X. O., Panopoulos, A. D., Nurieva, R., Chang, S. H., Wang, D., Watowich, S. S., & Dong, C. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.c600321200 · Cited by 1,530
Interleukin-2 Signaling via STAT5 Constrains T Helper 17 Cell Generation
Laurence, A., Tato, C. M., Davidson, T. S., Kanno, Y., Chen, Z., Yao, Z., Blank, R. B., Meylan, F., Siegel, R., Hennighausen, L., et al. (2007) · Immunity · doi:10.1016/j.immuni.2007.02.009 · Cited by 1,507
Sica, A., Schioppa, T., Mantovani, A., & Allavena, P. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.01.003 · Cited by 1,483
Generation of pathogenic TH17 cells in the absence of TGF-β signalling
Ghoreschi, K., Laurence, A., Yang, X.-P., Tato, C. M., McGeachy, M. J., Konkel, J. E., Ramos, H. L., Wei, L., Davidson, T. S., Bouladoux, N., et al. (2010) · Nature · doi:10.1038/nature09447 · Cited by 1,388
Almand, B., Clark, J. I., Nikitina, E., van Beynen, J., English, N. R., Knight, S. C., Carbone, D. P., & Gabrilovich, D. I. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.678 · Cited by 1,340
Bates, G. J., Fox, S. B., Cheng, H., Leek, R., García, J. F. S., Harris, A. L., & Banham, A. H. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.9584 · Cited by 1,244
Diaz-Montero, C. M., Salem, M. L., Nishimura, M. I., Garrett-Mayer, E. S., Cole, D. J., & Montero, A. J. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0523-4 · Cited by 1,217
Hirano, T., Ishihara, K., & Hibi, M. (2000) · Oncogene · doi:10.1038/sj.onc.1203551 · Cited by 1,207
The role of STATs in transcriptional control and their impact on cellular function
Bromberg, J., & Darnell, J. E. (2000) · Oncogene · doi:10.1038/sj.onc.1203476 · Cited by 1,201
Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer
Nagaraj, S., Gupta, K., Писарев, В. М., Kinarsky, L., Sherman, S., Kang, L., Herber, D. L., Schneck, J. P., & Gabrilovich, D. I. (2007) · Nature Medicine · doi:10.1038/nm1609 · Cited by 1,176
Tosolini, M., Kirilovsky, A., Mlecnik, B., Fredriksen, T., Mauger, S., Bindea, G., Berger, A., Bruneval, P., Fridman, W.-H., Pagès, F., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2907 · Cited by 1,146
CD4+ follicular helper T cell infiltration predicts breast cancer survival
Gu‐Trantien, C., Loi, S., Garaud, S., Equeter, C., Libin, M., de Wind, A., Ravoet, M., Buanec, H. L., Sibille, C., Manfouo-Foutsop, G., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67428 · Cited by 1,098
Chalmin, F., Ladoire, S., Mignot, G., Vincent, J., Bruchard, M., Rémy-Martin, J.-P., Boireau, W., Rouleau, A., Simon, B., Lanneau, D., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40483 · Cited by 1,029
Self-citationInhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity
Kortylewski, M., Kujawski, M., Wang, T., Sheng, W., Zhang, S., Pilon‐Thomas, S., Niu, G., Kay, H. D., Mulé, J. J., Kerr, W. G., et al. (2005) · Nature Medicine · doi:10.1038/nm1325 · Cited by 1,026
CD4 + Regulatory T Cells Control T H 17 Responses in a Stat3-Dependent Manner
Chaudhry, A., Rudra, D., Treuting, P., Samstein, R. M., Liang, Y., Kas, A., & Rudensky, A. Y. (2009) · Science · doi:10.1126/science.1172702 · Cited by 1,000
Regulatory T cells in tumor immunity
Nishikawa, H., & Sakaguchi, S. (2010) · International Journal of Cancer · doi:10.1002/ijc.25429 · Cited by 944
Cheng, P., Corzo, C. A., Luetteke, N., Yu, B., Nagaraj, S., Bui, M. M., Ortiz, M. L., Nacken, W. K. F., Sorg, C., Vogl, T., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080132 · Cited by 904
Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression
Wan, Y. Y., & Flavell, R. A. (2007) · Nature · doi:10.1038/nature05479 · Cited by 876
The Terminology Issue for Myeloid-Derived Suppressor Cells
Gabrilovich, D. I., Bronte, V., Chen, S., Colombo, M. P., Ochoa, A. C., Ostrand‐Rosenberg, S., & Schreiber, H. W. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3037 · Cited by 834
Tu, S., Bhagat, G., Cui, G., Takaishi, S., Kurt‐Jones, E. A., Rickman, B. H., Betz, K. S., Penz-Österreicher, M., Björkdahl, O., Fox, J. G., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.10.011 · Cited by 812
Stat3 Dimerization Regulated by Reversible Acetylation of a Single Lysine Residue
Yuan, Z.-L., Guan, Y.-J., Chatterjee, D., & Chin, Y. E. (2005) · Science · doi:10.1126/science.1105166 · Cited by 790
Mechanism Regulating Reactive Oxygen Species in Tumor-Induced Myeloid-Derived Suppressor Cells
Corzo, C. A., Cotter, M. J., Cheng, P., Cheng, F., Kusmartsev, S. A., Sotomayor, E. M., Padhya, T. A., McCaffrey, T. V., McCaffrey, J. C., & Gabrilovich, D. I. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900092 · Cited by 765
Possible involvement of the M2 anti‐inflammatory macrophage phenotype in growth of human gliomas
Komohara, Y., Ohnishi, K., Kuratsu, J., & Takeya, M. (2008) · The Journal of Pathology · doi:10.1002/path.2370 · Cited by 738
Zorn, E., Nelson, E. A., Mohseni, M., Porcheray, F., Kim, H. T., Litsa, D., Bellucci, R., Raderschall, E., Canning, C. M., Soiffer, R. J., et al. (2006) · Blood · doi:10.1182/blood-2006-02-004747 · Cited by 736
Marzec, M., Zhang, Q., Goradia, A., Raghunath, P. N., Liu, X., Paessler, M. E., Wang, H. Y., Wysocka, M., Cheng, M. M., Ruggeri, B., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810958105 · Cited by 731
Alexander, W. S., & Hilton, D. J. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.091003.090312 · Cited by 710
Tumor antigen-specific T helper cells in cancer immunity and immunotherapy
Knutson, K. L., & Disis, M. L. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-004-0653-2 · Cited by 697
Tumor‐induced tolerance and immune suppression by myeloid derived suppressor cells
Marigo, I., Dolcetti, L., Serafini, P., Zanovello, P., & Bronte, V. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00602.x · Cited by 626
Yu, J., Du, W., Fang, Y., Wang, Y., Li, H., Cao, S., Yu, W., Shen, C., Liu, J., & Ren, X. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201449 · Cited by 625
Stat3 mediates myeloid cell–dependent tumor angiogenesis in mice
Kujawski, M., Kortylewski, M., Lee, H., Herrmann, A., Kay, H. D., & Yu, H. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35213 · Cited by 594
Nonredundant roles for Stat5a/b in directly regulating Foxp3
Yao, Z., Kanno, Y., Kerenyi, M. A., Stephens, G. L., Durant, L. R., Watford, W. T., Laurence, A. D. J., Robinson, G. W., Shevach, E. M., Moriggl, R., et al. (2007) · Blood · doi:10.1182/blood-2006-11-055756 · Cited by 592
Harris, T. J., Grosso, J. F., Yen, H., Xin, H., Kortylewski, M., Albesiano, E., Hipkiss, E. L., Getnet, D., Goldberg, M. V., Maris, C. H., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.7.4313 · Cited by 592
CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling
Irie-Sasaki, J., Sasaki, T., Matsumoto, W., Opavsky, A., Cheng, M., Welstead, G. G., Griffiths, E. K., Krawczyk, C. M., Richardson, C. D., AITKEN, K. J., et al. (2001) · Nature · doi:10.1038/35053086 · Cited by 572
STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients
Vasquez-Dunddel, D., Pan, F., Zeng, Q., Gorbounov, M., Albesiano, E., Fu, J. L., Blosser, R. L., Tam, A. J., Bruno, T. C., Zhang, H., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci60083 · Cited by 522
IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation
Park, S.-J., Nakagawa, T., Kitamura, H., Atsumi, T., Kamon, H., Sawa, S.-I., Kamimura, D., Ueda, N., Iwakura, Y., Ishihara, K., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.6.3844 · Cited by 519
Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy
Durgeau, A., Virk, Y., Corgnac, S., & Mami‐Chouaib, F. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00014 · Cited by 507
Pillars Article: M-1/M-2 Macrophages and the Th1/Th2 Paradigm. J. Immunol. 2000. 164: 6166–6173
Mills, C. D., Kincaid, K., Alt, J., Heilman, M. J., & Hill, A. M. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1701141 · Cited by 494
Regulation of the IL-23 and IL-12 Balance by Stat3 Signaling in the Tumor Microenvironment
Kortylewski, M., Xin, H., Kujawski, M., Lee, H., Liu, Y., Harris, T., Drake, C. G., Pardoll, D. M., & Yu, H. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.018 · Cited by 489
Hiraoka, K., Miyamoto, M., Cho, Y., Suzuoki, M., Oshikiri, T., Nakakubo, Y., Itoh, T., Ohbuchi, T., Kondo, S., & Katoh, H. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602934 · Cited by 480
Regulation of gene-activation pathways by PIAS proteins in the immune system
Shuai, K., & Liu, B. (2005) · Nature reviews. Immunology · doi:10.1038/nri1667 · Cited by 467
Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer
Nefedova, Y., Huang, M., Kusmartsev, S., Bhattacharya, R., Cheng, P., Salup, R., Jove, R., & Gabrilovich, D. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.1.464 · Cited by 464
Tumor exosomes inhibit differentiation of bone marrow dendritic cells
Yu, S., Liu, C., Su, K., Wang, J., Liu, Y., Zhang, L., Li, C., Cong, Y., Kimberly, R., Grizzle, W. E., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.11.6867 · Cited by 425
Cheng, Y., Li, H., Deng, Y., Tai, Y., Zeng, K., Zhang, Y., Liu, W., Zhang, Q., & Yang, Y. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0458-4 · Cited by 414
Fang, W., Zhang, J., Hong, S., Zhan, J., Chen, N., Qin, T., Tang, Y., Zhang, Y., Kang, S., Zhou, T., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2608 · Cited by 408
Plasticity of myeloid-derived suppressor cells in cancer
Tcyganov, E., Mastio, J., Chen, E., & Gabrilovich, D. I. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.03.009 · Cited by 398
Agnello, D., Lankford, C. S. R., Bream, J. H., Morinobu, A., Gadina, M., O’Shea, J. J., & Frucht, D. M. (2003) · Journal of Clinical Immunology · doi:10.1023/a:1023381027062 · Cited by 388
Zhou, J., Li, X., Wu, X., Zhang, T., Zhu, Q., Wang, X., Wang, H., Wang, K., Lin, Y., & Wang, X. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0479 · Cited by 387
Schmitt, N., Liu, Y., Bentebibel, S.-E., Munagala, I. D., Bourdery, L., Venuprasad, K., Banchereau, J., & Ueno, H. (2014) · Nature Immunology · doi:10.1038/ni.2947 · Cited by 382
A Critical Role for Stat3 Signaling in Immune Tolerance
Cheng, F., Wang, H.-W., Cuenca, A., Huang, M., Ghansah, T., Brayer, J., Kerr, W. G., Takeda, K., Akira, S., Schoenberger, S. P., et al. (2003) · Immunity · doi:10.1016/s1074-7613(03)00232-2 · Cited by 377
Kumar, V., Cheng, P., Condamine, T., Mony, S., Languino, L. R., McCaffrey, J. C., Hockstein, N., Guarino, M., Masters, G., Penman, E., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.01.014 · Cited by 371
Zhang, N., Zeng, Y., Du, W., Zhu, J., Shen, D., Liu, Z., & Huang, J.-A. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3632 · Cited by 362
Chalmin, F., Mignot, G., Bruchard, M., Chevriaux, A., Végran, F., Hichami, A., Ladoire, S., Derangère, V., Vincent, J., Masson, D., et al. (2012) · Immunity · doi:10.1016/j.immuni.2011.12.019 · Cited by 338
Self-citationSTAT3 is required for Flt3L-dependent dendritic cell differentiation
Laouar, Y., Welte, T., Fu, X.-Y., & Flavell, R. A. (2003) · Immunity · doi:10.1016/s1074-7613(03)00332-7 · Cited by 334
Functional STAT3 deficiency compromises the generation of human T follicular helper cells
Ma, C. S., Avery, D. T., Chan, A., Batten, M., Bustamante, J. C., Boisson‐Dupuis, S., Arkwright, P. D., Kreins, A. Y., Averbuch, D., Engelhard, D., et al. (2012) · Blood · doi:10.1182/blood-2011-11-392985 · Cited by 330
IL-17 as a future therapeutic target for rheumatoid arthritis
van den Berg, W. B., & Miossec, P. (2009) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.179 · Cited by 325
Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis
Waight, J. D., Netherby, C. S., Hensen, M. L., Miller, A., Hu, Q., Liu, S., Bogner, P. N., Farren, M. R., Lee, K. P., Liu, K., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68189 · Cited by 325
Tumor microenvironments direct the recruitment and expansion of human Th17 cells
Su, X., Ye, J., Hsueh, E. C., Zhang, Y., Hoft, D. F., & Peng, G. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902813 · Cited by 324
Nefedova, Y., Nagaraj, S., Rosenbauer, A., Muro‐Cacho, C., Sebti, S. M., & Gabrilovich, D. I. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0529 · Cited by 318
Th17 cells: a new fate for differentiating helper T cells
Chen, Z. J., & O’Shea, J. J. (2008) · Immunologic Research · doi:10.1007/s12026-007-8014-9 · Cited by 309
Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma
Horlad, H., Komohara, Y., Okabe, H., Masuda, T., Ohnishi, K., Lei, X., Beppu, T., Baba, H., & Takeya, M. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01614.x · Cited by 280
Emmerich, J., Mumm, J. B., Chan, I. H., LaFace, D., Truong, H., McClanahan, T. K., Gorman, D. M., & Oft, M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0721 · Cited by 279
Nishihara, M., Ogura, H., Ueda, N., Tsuruoka, M., Kitabayashi, C., Tsuji, F., Aono, H., Ishihara, K., Huseby, E., Betz, U. A. K., et al. (2007) · International Immunology · doi:10.1093/intimm/dxm045 · Cited by 268
Ray, J. P., Marshall, H. D., Laidlaw, B. J., Staron, M. M., Kaech, S. M., & Craft, J. E. (2014) · Immunity · doi:10.1016/j.immuni.2014.02.005 · Cited by 242
Fu, X.-L., Duan, W., Su, C.-Y., Mao, F.-Y., Lv, Y.-P., Teng, Y.-S., Yu, P.-W., Zhuang, Y., & Zhao, Y.-L. (2017) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-017-2052-5 · Cited by 242
Gowrishankar, K., Gunatilake, D., Gallagher, S. J., Tiffen, J. C., Rizos, H., & Hersey, P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123410 · Cited by 238
STAT3 controls myeloid progenitor growth during emergency granulopoiesis
Zhang, H., Nguyen-Jackson, H., Panopoulos, A. D., Li, H. S., Murray, P. J., & Watowich, S. S. (2010) · Blood · doi:10.1182/blood-2009-12-259630 · Cited by 232
Kitamura, H., Kamon, H., Sawa, S.-I., Park, S.-J., Katunuma, N., Ishihara, K., Murakami, M., & Hirano, T. (2005) · Immunity · doi:10.1016/j.immuni.2005.09.010 · Cited by 223
Rébé, C., Végran, F., Berger, H., & Ghiringhelli, F. (2013) · JAK-STAT · doi:10.4161/jkst.23010 · Cited by 222
Self-citationSTAT3 in Cancer—Friend or Foe?
Zhang, H., & Lai, R. L. (2014) · Cancers · doi:10.3390/cancers6031408 · Cited by 219
Perrone, G., Ruffini, P. A., Catalano, V., Spino, C., Santini, D., Muretto, P., Spoto, C., Zingaretti, C., Sisti, V., Alessandroni, P., et al. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.05.017 · Cited by 217
Lamano, J. B., Lamano, J. B., Li, Y. D., DiDomenico, J. D., Choy, W., Veliceasa, D., Oyon, D. E., Fakurnejad, S., Ampie, L., Kesavabhotla, K., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2402 · Cited by 213
Burchill, M. A., Goetz, C. A., Prlic, M., O’Neil, J. J., Harmon, I., Bensinger, S. J., Turka, L. A., Brennan, P., Jameson, S. C., & Farrar, M. A. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.11.5853 · Cited by 211
Yoshimoto, T., Yoshimoto, T., Yasuda, K., Mizuguchi, J., & Nakanishi, K. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.7.4415 · Cited by 204
Laurence, A., Amarnath, S., Mariotti, J., Kim, Y. C., Foley, J., Eckhaus, M., O'Shea, J. J., & Fowler, D. H. (2012) · Immunity · doi:10.1016/j.immuni.2012.05.027 · Cited by 201
Hossain, D. M. S., Pal, S. K., Moreira, D., Duttagupta, P. A., Zhang, Q., Won, H., Jones, J. O., D’Apuzzo, M., Forman, S. J., & Kortylewski, M. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3145 · Cited by 192
Pleiotropic regulation of macrophage polarization and tumorigenesis by formyl peptide receptor-2
Li, Y., Cai, L., Wang, H., Wu, P., Gu, W., Chen, Y., Hao, H., Tang, K., Yi, P., Liu, M., et al. (2011) · Oncogene · doi:10.1038/onc.2011.112 · Cited by 192
IL-27 inhibits the development of regulatory T cells via STAT3
Huber, M., Steinwald, V., Guralnik, A., Brüstle, A., Kleemann, P., Rosenplänter, C., Decker, T., & Lohoff, M. D. (2007) · International Immunology · doi:10.1093/intimm/dxm139 · Cited by 191
Microalgae with Immunomodulatory Activities
Riccio, G., & Lauritano, C. (2019) · Marine Drugs · doi:10.3390/md18010002 · Cited by 191
Crowley, M. T., Inaba, K., & Steinman, R. M. (1990) · The Journal of Experimental Medicine · doi:10.1084/jem.172.1.383 · Cited by 190
Breast Cancer-Derived Exosomes Alter Macrophage Polarization via gp130/STAT3 Signaling
Ham, S., Lima, L. G., Chai, E. Z. P., Muller, A., Lobb, R. J., Krumeich, S., Wen, S., Wiegmans, A. P., & Möller, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00871 · Cited by 190
Xu, L., Kitani, A., Stuelten, C. H., McGrady, G., Fuss, I. J., & Strober, W. (2010) · Immunity · doi:10.1016/j.immuni.2010.09.001 · Cited by 187
SCHAPER, F., GENDO, C., ECK, M., SCHMITZ, J., GRIMM, C., ANHUF, D., KERR, I. M., & HEINRICH, P. C. (1998) · Biochemical Journal · doi:10.1042/bj3350557 · Cited by 178
FGFR2 Promotes Expression of PD-L1 in Colorectal Cancer via the JAK/STAT3 Signaling Pathway
Li, P., Huang, T., Zou, Q., Liu, D., Wang, Y., Tan, X., Yao, W., & Qiu, H. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1801199 · Cited by 174
Toward a new STATe: The role of STATs in mitochondrial function
Meier, J. A., & Larner, A. C. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2013.12.005 · Cited by 171
Austin, J. W., Lu, P., Majumder, P., Ahmed, R., & Boss, J. M. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302750 · Cited by 171
Immune Checkpoint Inhibitor Combinations in Solid Tumors: Opportunities and Challenges
Kyi, C., & Postow, M. A. (2016) · Immunotherapy · doi:10.2217/imt-2016-0002 · Cited by 166
Plasminogen Activator Inhibitor-1 Promotes the Recruitment and Polarization of Macrophages in Cancer
Kubala, M. H., Punj, V., Placencio-Hickok, V., Hua, F., Fernández, G. E., Sposto, R., & DeClerck, Y. A. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.10.082 · Cited by 166
STAT3 Modulation of Regulatory T Cells in Response to Radiation Therapy in Head and Neck Cancer
Oweida, A., Darragh, L. B., Phan, A. V., Binder, D. C., Bhatia, S., Mueller, A. C., Court, B. V., Milner, D. C., Raben, D., Woessner, R. D., et al. (2019) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djz036 · Cited by 162
Koh, J., Jang, J.-Y., Keam, B., Kim, S., Kim, M., Go, H., Kim, T. M., Kim, D., Kim, C. W., Jeon, Y. K., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1108514 · Cited by 157
Huang, X., Bai, X., Cao, Y., Wu, J., Huang, M., Tang, D., Tao, S., Zhu, T., Liu, Y., Yang, Y., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20090397 · Cited by 156
Fujiwara, Y., Komohara, Y., Ikeda, T., & Takeya, M. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01772.x · Cited by 153
Domínguez‐Soto, Á., Sierra‐Filardi, E., Puig‐Kröger, A., Pérez-Maceda, B. T., Gómez, F., Corcuera, M. T., Sánchez‐Mateos, P., & Corbí, A. L. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1000475 · Cited by 152
STAT3 regulates NF-κB recruitment to the IL-12p40 promoter in dendritic cells
Hoentjen, F., Sartor, R. B., Ozaki, M., & Jobin, C. (2004) · Blood · doi:10.1182/blood-2004-04-1309 · Cited by 143
Sirtuin-1 Activation Controls Tumor Growth by Impeding Th17 Differentiation via STAT3 Deacetylation
Limagne, E., Thibaudin, M., Euvrard, R., Berger, H., Châlons, P., Végan, F., Humblin, É., Boidot, R., Rébé, C., Dérangère, V., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.04.004 · Cited by 143
Self-citationHorlad, H., Ma, C., Yano, H., Pan, C., Ohnishi, K., Fujiwara, Y., Endo, S., Kikukawa, Y., Okuno, Y., Matsuoka, M., et al. (2016) · Cancer Science · doi:10.1111/cas.13065 · Cited by 139
Herrmann, A., Kortylewski, M., Kujawski, M., Zhang, C., Reckamp, K. L., Armstrong, B., Wang, L. Q., Kowolik, C. M., Deng, J., Figlin, R. A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0736 · Cited by 135
Migone, T., Cacalano, N. A., Taylor, N. N., Yi, T., Waldmann, T. A., & Johnston, J. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3845 · Cited by 135
STAT3 inhibition induces Bax-dependent apoptosis in liver tumor myeloid-derived suppressor cells
Guha, P., Gardell, J., Darpolor, J. K., Cunetta, M., Lima, M., Miller, G., Espat, N. J., Junghans, R. P., & Katz, S. C. (2018) · Oncogene · doi:10.1038/s41388-018-0449-z · Cited by 127
Ohno, Y., Kitamura, H., Takahashi, N., Ohtake, J., Kaneumi, S., Sumida, K., Homma, S., Kawamura, H., Minagawa, N., Shibasaki, S., et al. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1791-4 · Cited by 125
Kondo, K., Shaim, H., Thompson, P. A., Burger, J. A., Keating, M. J., Estrov, Z. E., Harris, D., Kim, E., Ferrajoli, A., Daher, M., et al. (2017) · Leukemia · doi:10.1038/leu.2017.304 · Cited by 124
Kujawski, M., Zhang, C., Herrmann, A., Reckamp, K. L., Scuto, A., Jensen, M. C., Deng, J., Forman, S. J., Figlin, R. A., & Yu, H. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1293 · Cited by 123
Straume, O., & Akslen, L. A. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19971021)74:5 · Cited by 123
Kortylewski, M., Kujawski, M., Herrmann, A., Yang, C., Wang, L., Liu, Y., Salcedo, R., & Yu, H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3031 · Cited by 122
Abdelhamed, S., Ogura, K., Yokoyama, S., Saiki, I., & Hayakawa, Y. (2016) · Journal of Cancer · doi:10.7150/jca.14713 · Cited by 122
Pivotal Role of STAT3 in Shaping Glioblastoma Immune Microenvironment
Piperi, C., Papavassiliou, K. A., & Papavassiliou, A. G. (2019) · Cells · doi:10.3390/cells8111398 · Cited by 120
Daino, H., Matsumura, I., Takada, K., Odajima, J., Tanaka, H., Ueda, S., Shibayama, H., Ikeda, H., Hibi, M., Machii, T., et al. (2000) · Blood · doi:10.1182/blood.v95.8.2577 · Cited by 115
Delgoffe, G. M., & Vignali, D. A. A. (2013) · JAK-STAT · doi:10.4161/jkst.23060 · Cited by 115
Thorn, M., Guha, P., Cunetta, M., Espat, N. J., Miller, G., Junghans, R. P., & Katz, S. C. (2016) · Cancer Gene Therapy · doi:10.1038/cgt.2016.19 · Cited by 113
Ma, L., Huang, C., Wang, X., Xin, D. E., Wang, L., Zou, Q. C., Zhang, Y. S., Tan, M.-D., Wang, Y.-M., Zhao, T. C., et al. (2017) · Molecular Cell · doi:10.1016/j.molcel.2016.12.002 · Cited by 113
Bazhin, A. V., von Ahn, K., Fritz, J., Werner, J. M., & Karakhanova, S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02129 · Cited by 111
Komohara, Y. (2011) · Oncology Reports · doi:10.3892/or.2011.1454 · Cited by 108
Giurisato, E., Xu, Q., Lonardi, S., Telfer, B. A., Russo, I., Pearson, A. J., Finegan, K. G., Wang, W., Wang, J., Gray, N. S., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1707929115 · Cited by 108
Cheng, F., Lienlaf, M., Wang, H.-W., Perez-Villarroel, P., Lee, C., Woan, K., Rock-Klotz, J., Sahakian, E., Woods, D., Pinilla-Ibarz, J., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302778 · Cited by 106
Iwata‐Kajihara, T., Sumimoto, H., Kawamura, N., Ueda, R., Takahashi, T., Mizuguchi, H., Miyagishi, M., Takeda, K., & Kawakami, Y. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002067 · Cited by 105
Insights Into the Molecular Mechanisms of T Follicular Helper-Mediated Immunity and Pathology
Qin, L., Waseem, T. C., Sahoo, A., Bieerkehazhi, S., Zhou, H. Y., Galkina, E., & Nurieva, R. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01884 · Cited by 100
STAT3 in CD8+ T Cells Inhibits Their Tumor Accumulation by Downregulating CXCR3/CXCL10 Axis
Yue, C., Shen, S., Deng, J., Priceman, S. J., Li, W., Huang, A., & Yu, H. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0014 · Cited by 100
S1PR1 Is Crucial for Accumulation of Regulatory T Cells in Tumors via STAT3
Priceman, S. J., Shen, S., Wang, L., Deng, J., Yue, C., Kujawski, M., & Yu, H. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.02.016 · Cited by 99
Ma, C. S., Wong, N. S. M., Rao, G., Nguyen, A., Avery, D. T., Payne, K. J., Torpy, J., O’Young, P., Deenick, E. K., Bustamante, J. C., et al. (2016) · The Journal of Experimental Medicine · doi:10.1084/jem.20151467 · Cited by 98
Wüest, T., Willette‐Brown, J., Durum, S. K., & Hurwitz, A. A. (2008) · Journal of Leukocyte Biology · doi:10.1189/jlb.1107778 · Cited by 95
Yin, T., Zhao, Z.-B., Guo, J., Wang, T., Yang, J.-B., Wang, C., Long, J., Ma, S., Huang, Q., Zhang, K., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3397 · Cited by 92
TH9 cells in anti-tumor immunity
Vargas, T. R., Humblin, É., Végran, F., Ghiringhelli, F., & Apétoh, L. (2016) · Seminars in Immunopathology · doi:10.1007/s00281-016-0599-4 · Cited by 88
Self-citationKong, L.-Y., Wei, J., Sharma, A. K., Barr, J., Abou-Ghazal, M. K., Fokt, I., Weinberg, J. S., Rao, G., Grimm, E. A., Priebe, W., et al. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0618-y · Cited by 87
Lee, J., Lee, G. T., Woo, S. H., Ha, Y., Kwon, S. J., Kim, W., & Kim, I. Y. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4563 · Cited by 87
Zhou, J., Qu, Z., Sun, F., Han, L., Li, L., Yan, S., Stabile, L. P., Chen, L., Siegfried, J. M., & Xiao, G. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0073 · Cited by 87
Zhang, Y., Ma, C. A., Lawrence, M. G., Break, T. J., O’Connell, M. P., Lyons, J. J., López, D., Barber, J. S., Zhao, Y., Barber, D. L., et al. (2017) · The Journal of Experimental Medicine · doi:10.1084/jem.20161427 · Cited by 85
Song, S., Yuan, P., Wu, H., Chen, J., Fu, J., Li, P., Lu, J., & Wei, W. (2014) · International Immunopharmacology · doi:10.1016/j.intimp.2014.02.027 · Cited by 84
Owaki, T., Asakawa, M., Morishima, N., Mizoguchi, I., Fukai, F., Takeda, K., Mizuguchi, J., & Yoshimoto, T. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.5.2903 · Cited by 80
Moreira, D., Adamus, T., Zhao, X., Su, Y.-L., Zhang, Z., White, S. V., Swiderski, P., Lu, X., DePinho, R. A., Pal, S. K., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1277 · Cited by 80
Mankan, A. K., & Greten, F. R. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.601739 · Cited by 77
Gene-based strategies for the immunotherapy of cancer
Tüting, T., Storkus, W. J., & Lotze, M. T. (1997) · Journal of Molecular Medicine · doi:10.1007/s001090050133 · Cited by 76
Spary, L. K., Salimu, J., Webber, J. P., Clayton, A., Mason, M. D., & Tabi, Z. (2014) · OncoImmunology · doi:10.4161/21624011.2014.955331 · Cited by 74
Hiwatashi, K., Tamiya, T., Hasegawa, E., Fukaya, T., Hashimoto, M., Kakoi, K., Kashiwagi, I., Kimura, A., Inoue, N., Morita, R., et al. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.04.024 · Cited by 74
Chen, M., Xiao, C., Lao, X., Yuan, W., Liu, R., Zeng, Q., Wang, J., Ouyang, F., Chen, D., Chan, K., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0329 · Cited by 74
Nucleus, mitochondrion, or reticulum? STAT3 à La Carte
Avalle, L., & Poli, V. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092820 · Cited by 74
Development of T follicular helper cells and their role in disease and immune system
Eivazi, S., Bagheri, S., Hashemzadeh, M. S., Ghalavand, M., Qamsari, E. S., Dorostkar, R., & Yasemi, M. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.10.083 · Cited by 72
Jiang, Y., Liu, Y., Li, J., Sun, S., Jin, W., Wang, X., & Dong, C. (2018) · Nature Communications · doi:10.1038/s41467-018-03852-2 · Cited by 71
Zhang, W., Zhang, J., Zhang, Z., Guo, Y., Wu, Y., Wang, R., Wang, L., Mao, S., & Yao, X. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.11.012 · Cited by 65
Targeting STAT3 and STAT5 in Tumor-Associated Immune Cells to Improve Immunotherapy
Verdeil, G., Lawrence, T., Schmitt‐Verhulst, A., & Auphan‐Anezin, N. (2019) · Cancers · doi:10.3390/cancers11121832 · Cited by 64
SOCS3 Transactivation by PPARγ Prevents IL-17–Driven Cancer Growth
Berger, H., Végran, F., Chikh, M., Gilardi, F., Ladoire, S., Bugaut, H., Mignot, G., Chalmin, F., Bruchard, M., Dérangère, V., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4018 · Cited by 61
Self-citationYu, H., Liu, Y., McFarland, B. C., Deshane, J. S., Hurst, D. R., Ponnazhagan, S., Benveniste, E. N., & Qin, H. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0004 · Cited by 61
Andersen, M. N., Etzerodt, A., Graversen, J. H., Holthof, L. C., Moestrup, S. K., Hokland, M., & Møller, H. J. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02301-3 · Cited by 61
Chen, W., Nyuydzefe, M. S., Weiss, J. M., Zhang, J., Waksal, S. D., & Zanin‐Zhorov, A. (2018) · Scientific Reports · doi:10.1038/s41598-018-35109-9 · Cited by 58
An oligonucleotide decoy for Stat3 activates the immune response of macrophages to breast cancer
Sun, Z., Yao, Z., Liu, S., Tang, H., & Xiong, Y. (2006) · Immunobiology · doi:10.1016/j.imbio.2005.11.004 · Cited by 57
Farren, M. R., Carlson, L. M., Netherby, C. S., Lindner, I., Li, P., Gabrilovich, D. I., Abrams, S. I., & Lee, K. P. (2014) · Science Signaling · doi:10.1126/scisignal.2004656 · Cited by 54
Read, K. A., Powell, M. D., Baker, C. E., Sreekumar, B. K. N., Ringel-Scaia, V. M., Bachus, H., Martin, R. E., Cooley, I. D., Allen, I. C., Ballesteros‐Tato, A., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1700106 · Cited by 54
Role of the HDAC6/STAT3 pathway in regulating PD-L1 expression in osteosarcoma cell lines
Keremu, A., Aimaiti, A., Liang, Z., & Zou, X. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3721-6 · Cited by 53
Li, D., Kong, C., Tsun, A., Chen, C., Song, H., Shi, G., Pan, W. Q., Dai, D., Shen, N., & Li, B. (2015) · Scientific Reports · doi:10.1038/srep14615 · Cited by 51
The ERBB-STAT3 Axis Drives Tasmanian Devil Facial Tumor Disease
Kosack, L., Wingelhofer, B., Popa, A., Orlova, A., Agerer, B., Vilagos, B., Májek, P., Parapatics, K., Lercher, A., Ringler, A., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2018.11.018 · Cited by 50
CD163 as a novel target gene of STAT3 is a potential therapeutic target for gastric cancer
Cheng, Z., Zhang, D., Gong, B., Wang, P., & Liu, F. (2017) · Oncotarget · doi:10.18632/oncotarget.20244 · Cited by 50
STAT3 Impairs STAT5 Activation in the Development of IL-9–Secreting T Cells
Olson, M. R., Verdan, F. F., Hufford, M. M., Dent, A. L., & Kaplan, M. H. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1501801 · Cited by 48
Solís-Martínez, R., Cancino-Marentes, M., Hernández-Flores, G., Ortiz-Lazareno, P., Mandujano-Álvarez, G., Cruz-Gálvez, C., Sierra-Díaz, E., Rodríguez-Padilla, C., Jave-Suárez, L. F., Aguilar-Lemarroy, A., et al. (2018) · Immunology Letters · doi:10.1016/j.imlet.2018.02.009 · Cited by 47
Anti-cancer versus cancer-promoting effects of the interleukin-17-producing T helper cells
Hemdan, N. Y. A. (2012) · Immunology Letters · doi:10.1016/j.imlet.2012.11.002 · Cited by 46
Importance of CD4+ Helper T-cells in Antitumor Immunity
Shiku, H. (2003) · International Journal of Hematology · doi:10.1007/bf02986610 · Cited by 43
Che, K. F., Shankar, E. M., Muthu, S., Zandi, S., Sigvardsson, M., Hinkula, J., Messmer, D., & Larsson, M. (2012) · Molecular Medicine · doi:10.2119/molmed.2012.00103 · Cited by 43
Jenkins, B. J., Grail, D., Inglese, M., Quilici, C., Bozinovski, S., Wong, P., & Ernst, M. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.4.1453-1463.2004 · Cited by 43
Wu, H., Xu, L., Teuscher, P., Liu, H., Kaplan, M. H., & Dent, A. L. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500335 · Cited by 40
Hercor, M., Anciaux, M., Denanglaire, S., Debuisson, D., Léo, O., & Andris, F. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.1hi1115-511r · Cited by 39
The tyrosine phosphatase SHP-1 dampens murine Th17 development
Mauldin, I. S., Tung, K. S. K., & Lorenz, U. M. (2012) · Blood · doi:10.1182/blood-2011-09-377069 · Cited by 36
STAT3 regulates cytotoxicity of human CD57+ CD4+ T cells in blood and lymphoid follicles
Alshekaili, J., Chand, R., Lee, C. E., Corley, S., Kwong, K., Papa, I., Fulcher, D. A., Randall, K. L., Leiding, J. W., Ma, C. S., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-21389-8 · Cited by 36
He, W., Zhu, Y., Mu, R., Xu, J., Zhang, X., Wang, C., Li, Q., Huang, Z. D., Zhang, J., Pan, Y., et al. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.08.019 · Cited by 34
Lam, E., Choi, S. H., Pareek, T. K., Kim, B.-G., & Letterio, J. J. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.06.015 · Cited by 32
Embelin impairs the accumulation and activation of MDSCs in colitis-associated tumorigenesis
Wu, T., Wang, C., Wang, W., Hui, Y., Zhang, R., Qiao, L., & Dai, Y. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1498437 · Cited by 29
Epigenetic Component p66a Modulates Myeloid-Derived Suppressor Cells by Modifying STAT3
Xin, J., Zhang, Z., Su, X., Wang, L., Zhang, Y., & Yang, R. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601712 · Cited by 28
Platelet Factor 4 Inhibits IL-17/Stat3 Pathway via Upregulation of SOCS3 Expression in Melanoma
Fang, S., Liu, B., Sun, Q., Zhao, J., Qi, H., & Li, Q. (2014) · Inflammation · doi:10.1007/s10753-014-9903-4 · Cited by 27
STAT3 Activation Impairs the Stability of Th9 Cells
Ulrich, B. J., Verdan, F. F., McKenzie, A. N. J., Kaplan, M. H., & Olson, M. R. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601624 · Cited by 26
Hu, J., Batth, I. S., Xia, X., & Li, S. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1252012 · Cited by 26
The differentiation and plasticity of Tc17 cells are regulated by CTLA-4-mediated effects on STATs
Arra, A., Lingel, H., Kuropka, B., Pick, J., Schnoeder, T. M., Fischer, T., Freund, C., Pierau, M., & Brunner-Weinzierl, M. C. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1273300 · Cited by 23
Li, H. S., Liu, C., Xiao, Y., Chu, F., Liang, X., Peng, W., Hu, J., Neelapu, S. S., Sun, S., Hwu, P., et al. (2016) · Science Signaling · doi:10.1126/scisignal.aaf3957 · Cited by 22
Mi, T., Wang, Z., & Bunting, K. D. (2018) · Cancers · doi:10.3390/cancers10100359 · Cited by 22
Wagner, A. H., Conzelmann, M., Fitzer, F., Giese, T., Gülow, K., Falk, C. S., Krämer, O. H., Dietrich, S., Hecker, M., & Luft, T. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.04.019 · Cited by 21
PM01183 Inhibits Myeloid-Derived Suppressor Cells In Vitro and In Vivo
Kuroda, H., Mabuchi, S., Kozasa, K., Yokoi, E., Matsumoto, Y., Komura, N., Kawano, M., Hashimoto, K., Sawada, K., & Kimura, T. (2017) · Immunotherapy · doi:10.2217/imt-2017-0046 · Cited by 19
Zhang, Y., Siegel, A., Sun, G., DiMaggio, T., Freeman, A. F., & Milner, J. D. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.06.036 · Cited by 19
Enhanced CD8 T cell cross-presentation by macrophages with targeted disruption of STAT3
Brayer, J. B., Cheng, F., Wang, H., Horna, P., Vicente-Suarez, I., Pinilla-Ibarz, J. A., & Sotomayor, E. M. (2010) · Immunology Letters · doi:10.1016/j.imlet.2010.03.004 · Cited by 19
Xiao, W., Yin, M., Wu, K., Lu, G., Deng, B., Zhang, Y., Li, Q., Jia, X., Ding, Y., & Gong, W. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12964 · Cited by 19
Docetaxel Down-Regulates PD-1 Expression via STAT3 in T Lymphocytes
Zhang, C., Li, F., Li, J., Xu, Y., Wang, L., & Zhang, Y. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.04.010 · Cited by 16
Novel Checkpoints and Cosignaling Molecules in Cancer Immunotherapy
Giuroiu, I., & Weber, J. S. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000241 · Cited by 15
Wang, X., XIN, W., Zhang, H., Zhang, F., GAO, M., Yuan, L., Xu, X., Hu, X., & Zhao, M. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2510 · Cited by 14
Sanseverino, I., Purificato, C., Varano, B., Conti, L., Gessani, S., & Gauzzi, M. C. (2014) · Immunobiology · doi:10.1016/j.imbio.2014.02.012 · Cited by 13
Cited by
Sorted by citations
IL-6 in inflammation, autoimmunity and cancer
Hirano, T. (2021) · International Immunology · doi:10.1093/intimm/dxaa078 · Cited by 1,453
“Furthermore, NF-κ B and STAT3 play crucial roles in cancer development and progression (19, 25, 67, 279).”
BackgroundInfluentialTargeting STAT3 in Cancer Immunotherapy
Zou, S., Tong, Q., Liu, B., Huang, W., Tian, Y., & Fu, X. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01258-7 · Cited by 1,109
Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer
Labrie, M., Brugge, J. S., Mills, G. B., & Zervantonakis, I. K. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00454-5 · Cited by 410
Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside
Lizardo, D. Y., Kuang, C., Hao, S., Yu, J., Huang, Y., & Zhang, L. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188447 · Cited by 216
Microalgae with Immunomodulatory Activities
Riccio, G., & Lauritano, C. (2019) · Marine Drugs · doi:10.3390/md18010002 · Cited by 191
Metadata
- Authors
- Rébé, C., & Ghiringhelli, F.
- Affiliations
- Inserm (FR)
- Corresponding author
- Rébé, Cédric
- Ghiringhelli, François
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2019-08-30
- Volume
- 11
- Issue
- 9
- Pages
- 1280
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC6770459
- OpenAlex
- W2970221585
- Cited by
- 129
- References
- 203
- Citations by year
- 2026: 13 · 2025: 22 · 2024: 29 · 2023: 17 · 2022: 14 · 2021: 13 · 2020: 16 · 2019: 5
- FWCI
- 1.17
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ligue Contre le Cancer (Equipe labélisée)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- STAT3, tumor immune microenvironment, antitumor immunity, transcription factors, immune cell activation, myeloid cells, lymphoid cells, STAT3 phosphorylation, STAT3 acetylation, immune checkpoint, tumor progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
